Senolytics: The “Zombie Cell” Drugs in Trials, and Why They Are Not for Sale

A reader wrote in last week with a screenshot. Her brother-in-law had forwarded a video promising that a compound found in strawberries would ‘flush the zombie cells out of your body in a weekend.’ Below it sat a link to a bottle. She wanted to know one thing: is any of this real?

The honest answer is more interesting than either the hype or the eye-roll. As of mid-2025, senolytics are among the most actively studied ideas in aging biology, with a steady trickle of small human trials in lung fibrosis, kidney disease, eye disease, and early Alzheimer’s keeping the term near the top of search. The interest is legitimate. The science is young.

What follows is the unglamorous version: what these drugs are, what a handful of pilot studies have and have not shown, why none of them is approved for aging, and why the supplement aisle is not a shortcut.

What are senolytics, and why is everyone suddenly talking about them?

Senolytics are drugs built to do something oddly specific: kill cells that have stopped dividing but refuse to die. The word comes from ‘senescence,’ the biological state of a cell that has permanently exited the cycle of growth and division, and ‘lytic,’ meaning to break apart. A senolytic, in other words, is a cell-clearing agent aimed at a single unwanted population.

The idea has a clean origin story. In 2011, researchers engineered mice so that senescent cells could be destroyed on command. When those cells were removed, the animals showed fewer cataracts, better muscle function, and less fat loss with age. Later mouse work found that clearing senescent cells in midlife extended median lifespan and delayed several age-related conditions. That is where the phrase ‘zombie cells’ entered the vocabulary of science journalism, and the label stuck because it is vivid: cells that are neither fully alive in the productive sense nor dead.

Why the current surge of attention? Three streams have converged. First, the first human data appeared in 2019 and small trials have continued to report since. Second, the geroscience field, which treats aging itself as a modifiable driver of disease rather than a fixed backdrop, has gained institutional backing, including a National Institute on Aging program that funds coordinated senolytic trials. Third, and least helpfully, the supplement industry noticed that two of the leading candidates, quercetin and fisetin, are plant flavonoids that can be bottled and sold without a prescription.

That last stream is the one most likely to reach you on a phone screen. The gap between what a mouse study showed and what a capsule can do is the central subject of this article. The short version: the concept is promising and the human proof is thin, which is exactly why these compounds are in trials rather than in pharmacies.

What senescent cells, the so-called zombie cells, actually do

Every cell in your body carries an emergency brake. When DNA is damaged beyond easy repair, when telomeres, the protective caps on chromosomes, wear too short, or when a cell receives a cancer-promoting signal, it can pull that brake and enter senescence. It stops dividing for good. This is, at first, a gift. A cell that cannot divide cannot become a tumor, and senescent cells help wounds heal and guide tissue during embryonic development.

The trouble is what happens next. A senescent cell does not sit quietly. It swells, changes shape, and begins secreting a cocktail of inflammatory molecules, growth factors, and tissue-dissolving enzymes. Researchers call this the senescence-associated secretory phenotype, or SASP, which simply means the set of substances a senescent cell pumps into its surroundings. Those substances can push neighboring healthy cells toward senescence too, which is why a small number of zombie cells can have an outsized effect on a tissue.

Normally the immune system sweeps these cells away. Natural killer cells and macrophages recognize and remove them. With age, though, two things change: senescent cells accumulate faster, and immune clearance slows, a phenomenon called immunosenescence, the age-related decline of immune function. The result is a growing backlog.

Senescent cells remain a minority. Even in older tissue, estimates from animal and human samples suggest they make up a small percentage of total cells. Their influence comes from the SASP, not from their numbers, which is why removing relatively few of them produced such striking results in mice.

One more caution belongs here. Senescence is not uniformly bad, and not all senescent cells are alike. Some protect against cancer. Some are essential to healing a cut. Any therapy that clears them must thread a needle: remove the harmful backlog without disabling a system the body still needs. That trade-off is why researchers speak of intermittent, targeted clearance rather than permanent eradication.

What changed recently: the trial timeline behind the buzz

The current wave of interest rests on a short but real record of human studies. Here is the dated sequence, tied to the sources at the end of this article.

In January 2019, the first-in-human senolytic study was published. Fourteen adults with idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs, took a brief course of dasatinib combined with quercetin in an open-label pilot. The study was designed to test feasibility and safety, not to prove benefit. Participants showed modest improvements on physical function tests such as walking distance and gait speed. There was no placebo group, so no one can say whether the drugs caused those changes.

In September 2019, a second small study followed in people with diabetic kidney disease. Nine participants received a short course of the same combination. Biopsies of fat tissue and skin taken afterward showed a reduction in cells carrying senescence markers, along with lower levels of some SASP molecules in blood. This was the first direct evidence that senolytics can decrease senescent cell burden in humans. Again: nine people, no placebo, no clinical outcomes measured.

In 2020, a comprehensive review in a mainstream medical journal laid out the case for moving from discovery to translation, while cautioning that human efficacy had not been demonstrated.

In 2021, the National Institute on Aging described cellular senescence as a priority research area and highlighted the launch of coordinated trials across multiple sites, with a stated goal of testing senolytics in conditions where senescent cells are thought to drive disease.

Since then, small trials have reported in early Alzheimer’s disease, in eye conditions using a locally injected BCL-xL inhibitor, and in frailty and bone health. Results have ranged from encouraging safety signals to disappointing efficacy readouts. As of mid-2025, the pattern has not changed: feasibility shown, biological effect suggested, clinical benefit unproven, and no approval for any aging indication.

What drugs are senolytics? The candidates in human trials

Ask ‘what drugs are senolytics’ and you will get a longer list than the evidence supports. The core candidates that have reached human studies are few.

Dasatinib plus quercetin. Dasatinib is a tyrosine kinase inhibitor, a drug that blocks certain enzymes cells use to send survival signals, approved for chronic myeloid leukemia under the brand name Sprycel. Quercetin is a flavonoid, a plant pigment compound, found in onions, apples, and capers. Alone, each clears only some types of senescent cells in the lab. Together they cover a wider range, which is why the pairing became the field’s workhorse combination.

Fisetin. Another flavonoid, present in small amounts in strawberries, apples, and persimmons. A 2018 study reported that it reduced senescence markers and extended lifespan in aged mice. Human trials are underway in older adults, but no efficacy results have established that oral fisetin clears senescent cells in people.

Navitoclax. An experimental cancer drug that inhibits BCL-2 family proteins, which are the molecular ‘do not die’ switches many senescent cells depend on. It is potent but carries a serious drawback discussed later.

UBX1325 (foselutoclax). A BCL-xL inhibitor injected directly into the eye, tested in diabetic macular edema and age-related macular degeneration. Local delivery is meant to avoid body-wide side effects. Phase 2 results have been mixed.

Beyond these sit compounds with lab or animal data only: piperlongumine, certain heat-shock protein inhibitors, cardiac glycosides, and engineered antibodies and immune cells designed to recognize senescent cell surface markers. None has meaningful human evidence yet.

A related category deserves a name because it is often confused with senolytics. Senomorphics are drugs that quiet the SASP without killing the cell. Rapamycin and metformin are the most discussed examples. They are not senolytics, and neither is approved for aging.

How senolytics work: finding the zombie's weak spot

The clever part of senolytic design is that it exploits the very thing that makes senescent cells dangerous: their refusal to die.

Most damaged cells commit apoptosis, a tidy, programmed form of cell death that recycles the parts without inflammation. Senescent cells resist apoptosis by switching on protective proteins. Researchers call these senescent cell anti-apoptotic pathways, or SCAPs, which is a technical way of saying the survival circuits a zombie cell leans on to stay alive. Healthy cells do not need those circuits at the same intensity.

A senolytic drug blocks one or more SCAPs. When the protection drops, the senescent cell, already primed for death by its own damage, tips over into apoptosis. Neighboring healthy cells, which were never relying on that circuit, are largely unaffected. That selectivity is the whole point, and it is why researchers describe the approach as pulling a crutch rather than swinging a hammer.

Different drugs target different crutches. Navitoclax and UBX1325 block BCL-2 family proteins. Dasatinib interferes with survival signaling through tyrosine kinases and appears especially effective against senescent fat-cell progenitors. Quercetin and fisetin act on several pathways at once, including a survival protein called PI3K, though with lower potency, which is part of why quercetin was paired with a stronger partner.

Timing matters as much as target. Because senescent cells take weeks to reaccumulate, trials have used brief, intermittent courses rather than continuous daily exposure. The theory, sometimes called ‘hit and run,’ is that short bursts clear the backlog while limiting the time healthy tissue is exposed. The specific regimens belong to trial protocols, not to readers, and they vary by drug and disease.

What the mechanism cannot tell you is whether clearing senescent cells in a human actually improves lung scarring, kidney function, or memory. Biology suggests it should. Only randomized trials can show that it does.

What the evidence actually says, graded honestly

Medical evidence comes in tiers, and the tier matters more than the headline. Here is where senolytics sit on each rung.

Laboratory and animal data: strong and consistent. Across dozens of mouse studies, clearing senescent cells genetically or with drugs has improved physical function, reduced frailty measures, delayed age-related disease, and in some experiments extended median lifespan. The effect is reproducible across labs. It is also, like all rodent work, an imperfect predictor of human results; mice are short-lived and their senescent cell biology differs in important ways.

Human biomarker data: preliminary. The 2019 diabetic kidney disease study showed that a short course of dasatinib plus quercetin reduced senescence markers in fat and skin tissue of nine participants. That is a genuine finding, but a biomarker changing is not a patient getting better.

Human functional data: pilot only. The idiopathic pulmonary fibrosis study reported improved walking distance and gait speed in fourteen people, with no placebo arm. Open-label designs are vulnerable to expectation effects and regression to the mean. The authors themselves framed the results as hypothesis-generating.

Randomized, placebo-controlled human data: essentially absent for clinical outcomes. Small randomized trials have begun, including in eye disease and in older adults with frailty, but none has yet demonstrated a convincing clinical benefit for an aging-related condition. Some have missed their primary endpoints.

Long-term safety data: none. No study has followed people for years after senolytic exposure to check for delayed harms such as impaired wound healing or effects on cancer risk.

Put together, the evidence supports exactly one conclusion: senolytics are worth testing rigorously. They do not yet support recommending them to anyone outside a trial. An expert consensus that a drug is ‘promising’ is the weakest form of evidence in medicine, and it is currently the strongest form available for senolytics in aging.

Senolytic candidates at a glance

The table below summarizes where each leading candidate stands. ‘Evidence grade’ refers to the strongest type of human evidence available for a senolytic use, not for the drug’s original purpose.

Candidate	What it is	Regulatory status	Strongest human evidence for senolytic use
Dasatinib + quercetin	Leukemia drug paired with a plant flavonoid	Dasatinib approved for leukemia only; combination investigational	Open-label pilots showing reduced senescence markers and feasibility; no placebo-controlled outcomes
Fisetin	Plant flavonoid	Sold as a dietary supplement; not approved as a drug for any purpose	Animal data; human trials ongoing without published efficacy results
Navitoclax	BCL-2 family inhibitor	Investigational cancer drug; not approved	Cancer trials only; dose-limiting low platelet counts
UBX1325 (foselutoclax)	BCL-xL inhibitor injected into the eye	Investigational	Phase 2 trials in retinal disease with mixed results
Senomorphics (rapamycin, metformin)	Drugs that dampen SASP without killing cells	Approved for transplant rejection and diabetes respectively; not for aging	Observational and small trials; not senolytics

Two patterns stand out. Every row that involves a prescription drug is either approved for something else entirely or not approved at all. Every row that involves a supplement rests on animal data. There is no cell in this table where ‘approved for aging’ and ‘randomized human benefit shown’ meet, and that empty intersection is the most important fact in the senolytic story right now.

The table will change. Several trials are scheduled to report over the next few years, and any one of them could move a candidate up a row. Until then, the grid is a map of open questions, not a menu.

Why senolytics are not for sale

The title of this article makes a plain claim, and it deserves a plain explanation. Senolytics are not for sale for aging because no regulator has approved one for that purpose, and the reasons are structural rather than bureaucratic.

Drug approval in the United States, the United Kingdom, and elsewhere requires evidence from adequately controlled trials that a medicine is safe and effective for a specific condition. Aging itself is not recognized as a disease indication by any major regulator. That is why senolytic trials are run in defined conditions such as pulmonary fibrosis, diabetic kidney disease, or macular degeneration, where a measurable outcome exists. Even in those conditions, no senolytic has yet met the bar.

Dasatinib illustrates the confusion. It is a legitimately approved medicine, but for chronic myeloid leukemia and a related leukemia. A prescription written for anti-aging purposes would be off-label, meaning outside the approved indication. Off-label prescribing is legal and sometimes appropriate when evidence supports it, but for senolytic use the evidence consists of pilot studies, and the drug carries meaningful hematologic and fluid-related risks. Whether that trade-off ever makes sense for an individual is a judgment only a treating clinician can make, ideally within a trial.

Navitoclax and UBX1325 are investigational, a term meaning they may be given only to enrolled trial participants under regulatory oversight. They cannot legally be sold to the public.

Quercetin and fisetin occupy a gray zone. They are sold as dietary supplements, which in the United States means the manufacturer, not a regulator, is responsible for safety before sale, and no claim to treat or prevent disease is permitted. A bottle labeled ‘senolytic’ is making an implied drug claim that the evidence does not support and the law does not allow.

The phrase ‘not for sale,’ then, is not a prohibition on curiosity. It is a statement about where the science stands: inside trials, where it belongs until the data mature.

Should I take senolytic supplements like fisetin or quercetin?

This is the question the reader with the screenshot was really asking, and it deserves a direct answer: there is no human evidence that over-the-counter senolytic supplements clear senescent cells or improve any measure of aging.

Consider what the trials actually used. In the human pilot studies, quercetin was not taken alone. It was paired with dasatinib, a prescription cancer drug, precisely because quercetin by itself is a weak senolytic in laboratory testing. A quercetin capsule is not half of a proven therapy; it is the weaker partner of an unproven one.

Fisetin’s story is similar. The 2018 mouse study that launched its reputation used amounts that, scaled to body weight, far exceed what a diet or typical supplement delivers, and mice metabolize flavonoids differently than humans do. Fisetin is also poorly absorbed from the gut and quickly broken down by the liver, so blood levels after an oral capsule are low and short-lived. Human trials in older adults are running, and until they publish, the honest status is ‘unknown.’

Then there is the matter of what is in the bottle. Dietary supplements in the United States are not tested by a regulator for purity or content before sale. Independent analyses of flavonoid supplements have found products with far less active compound than labeled, and occasionally with contaminants. The NIH Office of Dietary Supplements advises checking for third-party quality seals and, above all, discussing any supplement with a clinician, because flavonoids can interfere with how the liver processes certain prescription medicines, including some blood thinners and blood pressure drugs.

None of this makes quercetin or fisetin dangerous in the amounts found in food. It makes them unproven as therapies. If you are tempted, the most evidence-respecting step is to ask whether a clinical trial near you is recruiting, rather than to self-experiment. Trials come with monitoring, controls, and the chance to actually answer the question.

What foods have senolytics? Separating nutrition from pharmacology

Search ‘what foods have senolytics’ and you will be handed a produce list: strawberries, apples, onions, capers, kale, persimmons, grapes, cucumbers. The list is accurate as a catalog of where quercetin and fisetin occur naturally. It is misleading as a treatment plan.

Here is the scale problem. Strawberries are the richest common food source of fisetin, and even so the amount in a generous serving is measured in micrograms per gram of fruit. The mouse studies that showed senescent cell clearance delivered quantities that would translate, for a person, into eating a quantity of strawberries no one could realistically consume. Quercetin is more abundant, with onions and capers among the densest sources, but the same gap applies. Food delivers flavonoids at nutritional concentrations, not pharmacological ones.

Absorption compounds the issue. Flavonoids from whole foods are bound to sugars, partially broken down by gut bacteria, and heavily modified by the liver before they reach circulation. Whatever reaches your tissues bears little resemblance to the purified compound dropped onto cells in a dish.

So is the produce list useless? Not at all, just for a different reason. Diets rich in fruits, vegetables, and other flavonoid sources are consistently associated in large observational studies with lower rates of cardiovascular disease and lower overall mortality. The American Heart Association and the NHS recommend such eating patterns on that basis. Whether flavonoids themselves drive the benefit, or whether they simply travel with fiber, potassium, and fewer processed foods, remains debated. Either way, the association is real and the food is safe.

The distinction worth holding onto: eating strawberries is good nutrition supported by observational evidence. Eating strawberries to kill zombie cells is a pharmacological claim supported by nothing in humans. You can enjoy the first without believing the second.

How to remove senescent cells: what you can actually do today

People searching ‘how to remove senescent cells’ want a lever to pull now. There is no drug lever available outside a trial. There are, however, a few behaviors with at least early human evidence of reducing senescence markers, and they happen to be the same behaviors already recommended for other reasons.

Exercise. Small randomized trials in older adults have found that structured aerobic and resistance training over roughly three months reduced markers of cellular senescence in fat tissue and lowered circulating SASP-related molecules. These are biomarker studies with dozens of participants, not outcome trials, so the grade is ‘preliminary.’ The broader benefit of exercise on mortality and function, by contrast, is supported by decades of trial and observational evidence.

Weight management. Excess fat tissue is a major reservoir of senescent cells, and obesity accelerates their accumulation in animal and human studies. Observational data link healthier body composition to lower senescence markers. Whether intentional weight loss reverses the burden in humans is not yet established.

Calorie restriction. In rodents, sustained calorie restriction reduces senescent cell accumulation. Human data are sparse and come from small trials measuring biomarkers rather than outcomes.

Not smoking, and protecting sleep. Tobacco smoke is a potent inducer of senescence in lung and vascular cells. Chronic sleep disruption is associated with senescence markers in observational research. The evidence for quitting smoking on health outcomes is, of course, overwhelming irrespective of senescence.

What all these share is that they support the immune system’s own clearance machinery and reduce the rate of new senescent cells forming. None of them is a senolytic in the pharmacological sense, and none has been shown to ‘remove’ senescent cells the way a drug might. They are the sensible floor, not a miracle ceiling.

If you want to go further than the floor, the legitimate route is a registered clinical trial, where the compounds are real, the monitoring is careful, and your participation helps answer the question for everyone.

Common myths about senolytics, corrected

Viral claims about senolytics tend to repeat. Here are the most common, with what the evidence actually supports.

Myth: Senolytics have been shown to reverse aging in humans. They have not. The human studies published so far are pilot trials in specific diseases, measuring biomarkers or physical function in a few dozen people total. No trial has measured lifespan, and none has used a design capable of proving reversal of anything.

Myth: A supplement labeled ‘senolytic’ does what the trial drugs do. The prescription combination studied in humans included dasatinib, a potent leukemia drug. Quercetin or fisetin alone is a different and far weaker intervention, with no human evidence of senescent cell clearance.

Myth: Killing all senescent cells is the goal. Senescent cells suppress tumors, guide wound healing, and support tissue repair. Mouse studies have shown that eliminating certain senescent cells in the liver can cause blood vessel damage and fibrosis. The clinical aim is selective, intermittent clearance of a harmful excess, not eradication.

Myth: Because dasatinib is an approved drug, using it for aging is just a matter of getting a prescription. Approval is specific to chronic myeloid leukemia and related conditions. Off-label use for aging would rest on pilot data and carry real risks, including low blood counts, fluid around the lungs, and bleeding. Any such decision belongs to a treating clinician weighing an individual’s circumstances, and most experts would direct that person to a trial instead.

Myth: You can ‘feel’ your zombie cells being cleared. Senescent cells make up a small fraction of tissue and their removal produces no sensation. Any product promising a tangible detox feeling is describing something other than senolysis.

Myth: Rapamycin and metformin are senolytics. They are senomorphics, meaning they may dampen the SASP without killing senescent cells. Different mechanism, different evidence, same status: not approved for aging.

Each of these myths contains a seed of real science grown into a claim the data cannot hold. Trimming them back is not pessimism; it is respect for how much remains to be learned.

Risks and side effects of senolytics: what the trials have flagged

A drug that kills cells, even selectively, is never free of consequences. The senolytic candidates carry distinct risk profiles worth understanding.

Dasatinib. As a leukemia drug it has a well-documented side effect profile: suppression of blood cell production leading to low platelets and white cells, fluid retention including effusions around the lungs, diarrhea, headache, muscle pain, and increased bleeding risk. In the short senolytic pilot courses, reported effects were mostly mild, but the studies were small and brief. Dasatinib also interacts with medicines that alter stomach acid and with drugs processed by the same liver enzymes.

Quercetin and fisetin. Generally well tolerated in food and in typical supplement use, though high intakes have been associated with headache, digestive upset, and, in isolated reports, kidney concerns. Both can interfere with the metabolism of certain prescription drugs, including some anticoagulants, antibiotics, and blood pressure medicines. Their long-term safety at pharmacological levels has not been studied.

Navitoclax. Its defining problem is thrombocytopenia, a drop in platelets, because platelets rely on the same BCL-xL protein the drug inhibits. This has limited its development and prompted the design of next-generation compounds that spare platelets.

Locally injected agents such as UBX1325. Eye injections carry procedure-related risks including infection, inflammation, and raised eye pressure. Systemic effects are minimized but not absent.

Theoretical risks common to the class. Because senescent cells participate in wound healing and tumor suppression, researchers watch for impaired healing and any signal of increased cancer risk. No such signal has emerged in the short trials to date, but no trial has lasted long enough to rule it out.

These are the reasons regulated trials exist. Participants are screened, monitored with blood tests, and followed for adverse events. Someone taking a purchased compound alone has none of those safeguards, and a side effect that a trial would catch early might go unnoticed until it becomes serious.

When to see a doctor

Senolytics are not something you should be taking outside a trial, but the conversation around them still leads people to their clinicians, and it should. Two situations in particular call for an appointment.

Before starting anything marketed as a senolytic. If you are considering quercetin, fisetin, or any supplement promoted for clearing senescent cells, talk with the clinician who manages your medicines first. Flavonoid supplements can alter how the liver processes anticoagulants, certain antibiotics, some heart and blood pressure medicines, and drugs for transplant or autoimmune conditions. That conversation is also the right place to ask about clinical trials, which your clinician can help you locate and evaluate.

If you have already taken a senolytic compound and notice any of the following. Seek prompt medical attention for:

• Unexplained bruising, nosebleeds, bleeding gums, or blood in urine or stool, which can signal low platelets
• Shortness of breath, chest discomfort, or a dry cough that worsens when lying down, which can indicate fluid around the lungs
• Fever, chills, or recurrent infections, which may reflect suppressed white blood cells
• A wound or cut that is not healing over a normal timeframe
• Sudden vision changes, eye pain, or redness after any eye injection
• Severe or persistent diarrhea, dizziness, or fainting
• Reduced urination or swelling in the legs, which can indicate kidney strain

Call emergency services for chest pain, difficulty breathing, or heavy bleeding that will not stop.

One more circumstance deserves mention. If you are already prescribed dasatinib for leukemia, or rapamycin or metformin for their approved indications, do not change how you take them because of anything you read about senescent cells. Those medicines are doing a specific job at a specific dose set by your care team, and any adjustment, in either direction, is theirs to make.

The best outcome of the senolytic conversation is not a prescription. It is a well-informed patient and a clinician who knows what that patient is curious about.

Frequently asked questions

What is the most effective senolytic?

No one knows, because no head-to-head human trial has compared senolytics against each other or shown any of them to improve a clinical outcome. Dasatinib plus quercetin has the most human data, consisting of small pilot studies. Navitoclax is more potent in the lab but causes low platelets. Effectiveness in a dish or a mouse does not translate reliably to people, so the honest ranking is ‘all unproven.’

What drugs are senolytics?

The main candidates in human trials are dasatinib combined with quercetin, fisetin, navitoclax, and UBX1325 (foselutoclax), an eye-injected BCL-xL inhibitor. Dasatinib is approved for leukemia; the others are investigational or sold as supplements without drug approval. Rapamycin and metformin are often listed but are senomorphics, which dampen senescent cell signaling rather than killing the cells. None is approved for aging.

What foods have senolytics?

Strawberries, apples, persimmons, onions, capers, kale, and grapes contain fisetin or quercetin, the flavonoids studied as senolytics. The amounts are nutritional, not pharmacological; the mouse studies used quantities far beyond what a diet delivers, and gut and liver metabolism further limit what reaches tissues. These foods are worth eating for their well-documented association with lower cardiovascular risk, not for any proven zombie-cell effect.

How can I eliminate senescent cells from my body?

No proven method exists outside clinical trials. Small human studies suggest regular exercise reduces senescence markers in fat tissue, and animal data link healthy weight and calorie restriction to slower accumulation. Not smoking removes a major driver of new senescent cells. Your immune system clears senescent cells naturally, and these habits support that process. Purchased supplements have not been shown to remove senescent cells in people.

Are senescent cells always harmful?

No. Senescent cells suppress tumors by refusing to divide, guide wound healing, and shape tissues during development. Harm arises when they accumulate beyond the immune system’s ability to clear them and their inflammatory secretions spread to neighbors. Mouse studies show that removing certain senescent cells in the liver can damage blood vessels, which is why researchers aim for selective, intermittent clearance rather than total elimination.

Do senolytic supplements work?

There is no human evidence that supplements containing quercetin or fisetin clear senescent cells or improve any aging measure. The human pilot trials paired quercetin with dasatinib, a prescription cancer drug, because quercetin alone is weak. Fisetin’s reputation rests on mouse data; human trials are ongoing without published efficacy results. Supplement quality also varies, and flavonoids can interact with prescription medicines, so discuss any product with your clinician.

Why are senolytics not approved for aging?

Regulators approve drugs for specific diseases based on controlled trials showing safety and benefit, and aging itself is not a recognized indication. Senolytics are therefore tested in defined conditions such as pulmonary fibrosis and kidney disease, and no candidate has yet demonstrated clinical benefit in a randomized trial. Dasatinib’s approval covers leukemia only, and navitoclax and UBX1325 remain investigational, meaning available solely to enrolled trial participants.

What are the side effects of senolytic drugs?

Dasatinib can lower platelets and white cells, cause fluid around the lungs, and raise bleeding risk. Navitoclax’s main problem is thrombocytopenia. Quercetin and fisetin are generally well tolerated in food but can interact with anticoagulants and other prescription drugs at supplement levels. Theoretical class-wide concerns include impaired wound healing and effects on cancer risk, which no trial has yet been long enough to assess.

Is rapamycin a senolytic?

No. Rapamycin is a senomorphic, a drug that may dampen the inflammatory secretions of senescent cells without killing them. It is approved to prevent organ transplant rejection and for certain rare conditions, not for aging. Its longevity reputation comes mainly from mouse studies. Anyone prescribed rapamycin should take it exactly as directed and never adjust it based on anti-aging claims.

Can I join a senolytic clinical trial?

Possibly. Several trials funded by the National Institute on Aging and others are recruiting adults with specific conditions such as frailty, lung fibrosis, kidney disease, or early Alzheimer’s, and some enroll healthy older adults for safety studies. Ask your clinician to help you search registries and assess eligibility. Trials provide real compounds under monitoring, which is the only responsible way to take a senolytic today.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.